Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 6Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × lonafarnib × Clear all
NCT00102635 2018-11-15

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Head & Neck

Head and Neck Neoplasms

NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Emory University

Phase 1 Terminated
38 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡